 |
市場調查報告書
商品編碼
1983180
創傷後壓力症候群 (PTSD) 治療市場：按藥物類別、給藥途徑、年齡層、分銷管道和地區分類Post-traumatic Stress Disorder Treatment Market, By Drug Class, By Route of Administration, By Age Group By Distribution Channel, By Geography |
||||||
價格
簡介目錄
2026年，創傷後壓力症候群（PTSD）治療市場規模預計為12.59億美元，預計到2033年將達到17.835億美元。預計從2026年到2033年，該市場將以5.1%的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 12.59億美元 |
| 業績數據週期： | 2020-2024 | 預測期： | 2026-2033 |
| 2026-2033年預測期間的複合年成長率： | 5.10% | 2033年市場規模預測： | 17.835億美元 |
創傷後壓力症候群（PTSD）是一種精神疾病，可能發生在經歷創傷性事件的人身上，例如自然災害、危及生命的事件、車禍或性虐待。 PTSD的症狀可能在三個月甚至一年後才會出現。許多PTSD患者會出現侵入性記憶、逃避行為、負面思考模式改變、情緒和生理反應異常等症狀。例如，親人的突然離世可能會誘發某些人的PTSD。 PTSD患者的危險感知能力會顯著增強。根據美國國家創傷後壓力症候群中心估計，約有15%的越戰老兵和約12%的海灣戰爭老兵患有PTSD。美國精神醫學會指出，女性罹患PTSD的可能性是男性的兩倍。治療創傷後壓力症候群的常用藥物包括抗憂鬱症、舍曲林、Fluoxetine和帕羅西汀。
市場動態
主要市場公司加大創傷後壓力症候群（PTSD）治療的研發活性化，預計將在預測期內推動全球PTSD治療市場成長。例如，2021年12月，製藥公司Jazz Pharmaceuticals plc.宣布其首批患者已完成入組，該試驗旨在評估JZP150的安全性和有效性。 JZP150是一種First-in-Class的小分子化合物，目前正在開發用於治療成人PTSD患者。 JZP150是一種高選擇性脂肪酸醯胺水解酵素（FAAH）抑制劑，旨在解決PTSD的根本原因（恐懼消退和固著障礙）以及焦慮、失眠和噩夢等相關症狀。
本次調查的主要特點。
- 本報告詳細分析了 2022 年至 2030 年預測期間全球創傷後壓力症候群 (PTSD) 治療市場的規模，以 2021 年為基準年。
- 本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
- 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本報告根據以下參數分析了全球創傷後壓力症候群 (PTSD) 治療市場的主要企業：公司概況、財務績效、產品系列、企業發展區域、分銷策略、關鍵發展和策略。
- 透過利用本報告中的見解，企業負責人和經營團隊將能夠就未來的產品發布、政府主導的舉措、技術升級、市場擴張和行銷策略做出明智的決策。
- 本報告面向該行業的眾多相關人員，包括投資者、產品製造商、經銷商、供應商、研究和諮詢公司、新參與企業和金融分析師。
- 相關人員可以透過分析全球創傷後壓力症候群 (PTSD) 治療市場中使用的各種策略矩陣來促進決策。
目錄
第1章：研究目標與前提條件
- 研究目標
- 前提
- 簡稱
第2章 市場範圍
- 報告摘要
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 市場趨勢
- 主要進展
- 產品核准
- 合作關係、併購
- 監理情勢
- PEST分析
- 波特五力分析
- 流行病學
- 強大的管道分析
第4章 全球創傷後壓力症候群（PTSD）治療市場：依藥物類別分類，2026-2033年
- 抗憂鬱症
- 抗焦慮藥物
- 抗高血壓藥物
- 單胺氧化酵素（MAO）抑制劑
- 抗精神病藥物或第二代抗精神病藥物（SGOs）
- BETA阻斷劑
- 其他（苯二氮平類藥物及其他）
第5章 全球創傷後壓力症候群（PTSD）治療市場：依給藥途徑分類，2026-2033年
- 口服
- 腸外
- 鼻內
第6章 全球創傷後壓力症候群（PTSD）治療市場：依年齡層別分類，2026-2033年
- 兒童
- 成人
- 老年人
第7章 全球創傷後壓力症候群（PTSD）治療市場：依通路分類，2026-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第8章 全球創傷後壓力症候群（PTSD）治療市場：按地區分類，2026-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第9章 競爭情勢
- 熱圖分析
- 市佔率分析
- 公司簡介
- Jazz Pharmaceuticals plc.
- Madrigal Mental Care
- Allergan PLC
- Otsuka Pharmaceutical Co., Ltd.
- apex laboratories Pvt. Ltd.
- H. Lundbeck A/S（Lundbeck）
- Neurovation Labs, Inc.
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Sun Pharmaceuticals Pvt Ltd
- Bristol-Myers Squibb
- Johnson and Johnson
- Pfizer Inc.
- Aurobindo Inc.
- Amneal Pharmaceuticals LLC
- Teva Pharmaceuticals Industries Ltd.
- Mylan Pharmaceuticals（Viatris Inc.）
第10章
- 參考
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI4433
Post-traumatic Stress Disorder Treatment Market is estimated to be valued at USD 1,259 Mn in 2026 and is expected to reach USD 1,783.5 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,259 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.10% | 2033 Value Projection: | USD 1,783.5 Mn |
Post-traumatic stress disorder (PTSD) is a psychiatric condition that may occur in people who have witnessed a traumatic shock like natural disaster, a life threatening event, car accident, sexual abuse etc. Symptoms of PTSD may generate after three months or even after a year. Most of the patients suffering from PTSD show symptoms like intrusive memories, avoidance, negative changes in thinking and changes in emotional and physical reactions. For instance, sudden death of a loved one may cause PTSD in some people. People with PTSD have heightened sense of danger. According to the U.S. National centre for PTSD, it is estimated that about 15% of the veterans of Vietnam War and 12% of gulf war veterans have PTSD. According to American Psychiatric Association, women are twice likely to get PTSD as compared to men. Commonly prescribed drugs for post trauma stress disorder includes antidepressants, sertraline, fluoxetine, paroxetine, and others.
Market Dynamics
Increasing research and development activities by the key market players for the treatment of post-traumatic stress disorder is expected to boost the growth of the global post-traumatic stress disorder treatment market over the forecast period. For instance, in December 2021, Jazz Pharmaceuticals plc. a pharmaceutical company, announced that the company had enrolled its first patient in Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD). JZP150 is a highly selective inhibitor of the enzyme Fatty Acid Amide Hydrolase (FAAH), designed to address the underlying cause of PTSD (impairment of fear extinction and its consolidation), as well as patient's associated symptoms such as anxiety, insomnia, and nightmares.
Key features of the study
- This report provides an in-depth analysis of the global post-traumatic stress disorder treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 - 2030, considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global post-traumatic stress disorder treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Jazz Pharmaceuticals plc., Madrigal Mental Care, Allergan PLC, Otsuka Pharmaceutical Co., Ltd., apex laboratories Pvt. Ltd., H. Lundbeck A/S (Lundbeck), Neurovation Labs, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Sun Pharmaceuticals Pvt Ltd, Bristol-Myers Squibb, Johnson and Johnson, Pfizer Inc., Aurobindo Inc., Amneal Pharmaceuticals LLC, Teva Pharmaceuticals Industries Ltd., and Mylan Pharmaceuticals (Viatris Inc.)
- Insights from this report would allow marketers and management authorities of companies to make an informed decision for their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global post-traumatic stress disorder treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global post-traumatic stress disorder treatment market
Market Segmentation
- By Drug Class
- Antidepressants
- Anti-anxiety
- Antihypertensive
- Monoamine Oxidase (MAOs)
- Antipsychotics or Second-Generation Antipsychotics (SGOs)
- Beta-Blockers
- Others (Benzodiazepines and Others)
- By Route of Administration
- Oral
- Parenteral
- Nasal
- By Age Group
- Pediatric
- Adult
- Geriatric
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Jazz Pharmaceuticals plc.
- Madrigal Mental Care
- Allergan PLC
- Otsuka Pharmaceutical Co., Ltd.
- apex laboratories Pvt. Ltd.
- Lundbeck A/S (Lundbeck)
- Neurovation Labs, Inc.
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Sun Pharmaceuticals Pvt Ltd
- Bristol-Myers Squibb
- Johnson and Johnson
- Pfizer Inc.
- Aurobindo Inc.
- Amneal Pharmaceuticals LLC
- Teva Pharmaceuticals Industries Ltd.
- Mylan Pharmaceuticals (Viatris Inc.)
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Age Group
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Post-traumatic Stress Disorder Treatment Market, By Drug Class, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026- 2033
- Segment Trends
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Anti-anxiety
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Antihypertensive
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Monoamine Oxidase (MAOs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Antipsychotics or Second-Generation Antipsychotics (SGOs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Beta-Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Others (Benzodiazepines and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
5. Global Post-traumatic Stress Disorder Treatment Market, By Route of Administration, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
6. Global Post-traumatic Stress Disorder Treatment Market, By Age Group, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
7. Global Post-traumatic Stress Disorder Treatment Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
8. Global Post-traumatic Stress Disorder Treatment Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Jazz Pharmaceuticals plc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Madrigal Mental Care
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Allergan PLC
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- apex laboratories Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- H. Lundbeck A/S (Lundbeck)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Neurovation Labs, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sun Pharmaceuticals Pvt Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Aurobindo Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Amneal Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Teva Pharmaceuticals Industries Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Mylan Pharmaceuticals (Viatris Inc.)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Market Strategies
- Analyst Views
10. Section
- References
- Research Methodology
- About Us
